Clinical Trial Update: A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi [Phase 2]

View source ↗

Summary

Phase 2 study in Huntington's disease evaluating safety, tolerability, pharmacokinetics, and efficacy of Pepi has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• Pepi

Snippet

Sponsor: Vaccinex Inc. | Conditions: Huntington's Disease | Phase 2 | Status: COMPLETED